In summary, our studies provide evidence, for the first time, that LCN2 is highly upregulated in IBC tumors and that it is required for tumor growth and skin invasion in mouse models of IBC; our findings further suggest that LCN2 could be a therapeutic target for IBC and other aggressive cancers. This evidence concerns the gene LCN2 and inflammatory breast carcinoma.